A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
← catalyst calendarNCT07082738 · readout in 443 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
987estimated
Sites
368
Countries
Argentina, Australia, Bulgaria +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-27 | actual | When the study began enrolling |
| Primary completion | 2027-11-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- Drug: AZD6793
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualised rate of moderate or severe COPD exacerbations
measured From baseline up to 24 Weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed